Melanotan I and Afamelanotide Research Guide: MC1R Biology and Product Distinctions
Melanotan I and Afamelanotide Research Guide: MC1R Biology and Product Distinctions
A primary-source review of NDP-alpha-MSH pigmentation studies and afamelanotide trials that separates peptide lineage from formulation equivalence.
One peptide lineage, several very different evidence contexts
Melanotan I is a research-market name associated with Nle4-D-Phe7-alpha-MSH, or NDP-alpha-MSH. This linear analog activates melanocortin-1 receptor signaling in melanocytes and has been studied through pigmentation, pigment chemistry, and pharmacokinetic endpoints.
Later clinical literature uses the name afamelanotide and evaluates standardized formulations in specific diseases such as erythropoietic protoporphyria or in a combination intervention for vitiligo. Those trials are important human evidence, but they do not validate gray-market or research-vial manufacturing.
Pigmentation is not a proxy for ultraviolet safety. The guide should never imply that a change in pigment prevents sunburn, DNA damage, photoaging, or skin cancer.
What researchers are trying to understand
How are Melanotan I and afamelanotide related?
Both names refer to the NDP-alpha-MSH peptide lineage, but afamelanotide trials used defined clinical formulations. A research product cannot claim formulation equivalence from the shared name alone.
What pathway is being studied?
NDP-alpha-MSH is studied primarily through MC1R-linked cyclic-AMP signaling and melanogenesis in melanocytes.
Does more pigment prove protection from UV injury?
No. Pigmentation endpoints do not establish protection from sunburn, DNA damage, photoaging, or skin cancer.
Notable studies, in plain English
The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.
Skin pigmentation and pharmacokinetics of melanotan-I in humans
- Model
- Human
- Design
- Randomized crossover pharmacokinetic and pigmentation pilot in three male volunteers.
What the paper reported: The study characterized early human exposure and pigmentation measures for melanotan-I.
Important limit: Three participants and surrogate endpoints cannot characterize efficacy, long-term safety, or product equivalence.
Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans
- Model
- Human
- Design
- Seven-volunteer mechanistic study using skin biopsies and pigment chemistry.
What the paper reported: The authors reported increased eumelanin-related measures in sampled skin.
Important limit: Very small study with no demonstration of ultraviolet protection or long-term safety.
Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo: A Randomized Multicenter Trial
- Model
- Human
- Design
- Randomized multicenter trial in 55 participants comparing a defined afamelanotide-plus-phototherapy intervention with phototherapy context.
What the paper reported: The trial evaluated repigmentation outcomes in a specific vitiligo population and combination design.
Important limit: Combination treatment prevents attribution to an unrelated research vial and does not support cosmetic or general claims.
Afamelanotide for Erythropoietic Protoporphyria
- Model
- Human
- Design
- Two multicenter, randomized, double-blind, placebo-controlled trials using standardized afamelanotide implants in European and US cohorts.
What the paper reported: The trials evaluated pain-free light exposure and disease-specific quality-of-life outcomes in erythropoietic protoporphyria.
Important limit: Rare-disease implant evidence does not establish cosmetic use, broad photoprotection, or equivalence of a research vial.
What the evidence does—and does not—establish
The early Melanotan-I studies were extremely small and focused on pharmacokinetics or pigment measures. They cannot define long-term safety or ultraviolet-risk reduction.
The larger controlled evidence concerns standardized afamelanotide formulations in specific diseases. Shared peptide lineage is not proof that a separately manufactured research powder has the same purity, formulation, delivery, stability, or performance.
Avoid tanning instructions and avoid presenting pigmentation as sun protection. Those are different scientific and safety questions.
- Melanotan I is associated with the NDP-alpha-MSH sequence.
- Early human studies were tiny and biomarker-focused.
- Later afamelanotide trials used standardized clinical formulations.
- Pigmentation does not prove UV protection.
- Research-lot identity must be tested independently.
Where to buy Melanotan I for laboratory research in the USA
A research listing should disclose the full linear sequence, terminal chemistry, salt or counterion, observed mass, chromatographic purity, quantity, and lot number. It should clarify whether the seller uses Melanotan I as a synonym for NDP-alpha-MSH or another material.
Review the lot-specific COA, chromatogram, test date, storage documentation, fulfillment origin, and support contact. Clinical afamelanotide citations should be educational context only, never a substitute for product testing or an invitation to human use.
Searches such as “where to buy Melanotan I,” “buy Melanotan I USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.
Melanotan I research FAQ
Are Melanotan I and afamelanotide the same?
They refer to the same peptide-development lineage, but later afamelanotide evidence also depends on controlled pharmaceutical formulations. Product equivalence must be demonstrated, not assumed.
Is Melanotan I the same as Melanotan II?
No. Melanotan I is a linear NDP-alpha-MSH analog; Melanotan II is a shorter cyclic analog with broader receptor activity.
Does pigmentation show that UV exposure is safe?
No. Pigmentation does not establish protection from sunburn, DNA injury, photoaging, or skin cancer.
Can an afamelanotide implant trial validate a research powder?
No. Formulation, manufacturing, release profile, purity, and intended use differ.
What should a Melanotan I COA show?
It should connect a specific lot to the disclosed sequence, observed mass, chromatographic purity, test date, and responsible test method or laboratory.
Primary references
References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.
- Ugwu SO et al. Biopharmaceutics & Drug Disposition. 1997;18(3):259-269. PMID 9113347. DOI 10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X.
- Dorr RT et al. Photochemistry and Photobiology. 2000;72:526-532. PMID 11045725. DOI 10.1562/0031-8655(2000)072<0526:IEEATI>2.0.CO;2.
- Lim HW et al. JAMA Dermatology. 2015. PMID 25230094. DOI 10.1001/jamadermatol.2014.1875.
- Langendonk JG et al. New England Journal of Medicine. 2015;373:48-59. PMID 26132941. DOI 10.1056/NEJMoa1411481.